@LipidJournal
🇺🇸Account based in!
About this account
- Account based in
- United States
- Connected via
- Web
X says this location may be affected by a proxy or VPN.
Account-level information from X, not a live location or the device used for a specific post.
The Journal of Clinical Lipidology is a leading peer-reviewed journal covering clinical lipidology. Editors-in-Chief: P. Barton Duell, MD & Anne C. Goldberg, MD
Jacksonville, FL
Joined May 2017
- Tweets198
- Following2.5K
- Followers3.9K
- Likes170
#JCLSpotlight: Sitosterol is highly effective for identifying ST, but its diagnostic performance declines in gray zone cases. A combined sterol-based model improves discrimination & supports a stepwise diagnostic strategy for children with suspected ST. 🔗ow.ly/x4Ey50ZZJq8
#JCLSpotlight: Infants of mothers living with ASCVD, but not those with FH, had higher risks of adverse birth outcomes and increased healthcare utilization in this retrospective US cohort study. 🔗ow.ly/L9aF50ZZJbz
#JCLSpotlight: NMR-derived total HDL particle concentration, rather than HDL-C, is independently associated with all-cause mortality in LTRs. HDL-P captures dimensions of HDL not reflected by HDL-C and could be an important mortality biomarker. 🔗ow.ly/6SR350ZZIXJ
We're thrilled to share that Daniel Gaudet, MD, PhD and Michael Miller, MD have been promoted from Associate Editors to Deputy Editors of the JCL. Their contributions have been invaluable & this is a well-deserved recognition of the impact they continue to make on the field.
Journal of Clinical Lipidology retweeted
🤔How safe are nonstatin LDL-C–lowering therapies?
👉New meta-analysis in @LipidJournal
1⃣ 41 randomized trials, 104,672 participants
2⃣ No increase in overall adverse events (RR 1.00) or serious adverse events (RR 0.98).
3⃣ No significant muscle, hepatic, or neurocognitive safety signals.
4⃣ Modest increase in discontinuations due to adverse events (RR 1.08) and investigator-attributed drug-related events (RR 1.23).
5⃣ Bempedoic acid: lower myalgia risk (RR 0.85)
👆 Clinical takeaway: Fear of serious toxicity should not be a barrier to appropriate LDL-C lowering. These findings support the safety of nonstatin therapies and their use in combination strategies when indicated
🔗 doi.org/10.1016/j.jacl.2026.…
@nationallipid
@society_eas
#JCLSpotlight from the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline Special Issue: "Imaging guided treatment of subclinical atherosclerosis—We’ve come a long way!"
Read now: ow.ly/VTsw50ZXAjB
Read the entire issue: ow.ly/xLKq50ZXAjy
#JCLSpotlight: "Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review"
JCL Social Media Ambassador @drpablocorral shares his key highlights.🔍
Read the full article: lipidjournal.com/article/S19…
👉Lp(a)HORIZON: could tolerability and treatment exposure have influenced the result?
👆Targeted Lp(a)-lowering therapies: tolerability matters too.
1⃣ Emerging therapies achieve substantial Lp(a) reductions, with generally favorable safety profiles in early trials.
2⃣ In pelacarsen’s phase 2 trial, injection-site reactions occurred in 27% vs 6% with placebo, while discontinuation due to adverse events was similar: 5% vs 4%.
3⃣ More local reactions do not necessarily translate into treatment withdrawal or reduced exposure.
4⃣ Comparisons across agents require caution: dosing schedules, follow-up and adverse-event reporting differ between trials.
5⃣ Adherence and sustained Lp(a) lowering may help contextualize cardiovascular outcome findings, including HORIZON. Any contribution of treatment interruptions to its negative result remains speculative.
Substantial Lp(a) lowering is established. Its translation into cardiovascular benefit remains the key question.
The depth and duration of Lp(a) lowering may matter. Whether reduced treatment exposure contributed to HORIZON’s result remains an open question.
🔗doi.org/10.1016/j.jacl.2026.…
@society_eas
@LipidJournal
@nationallipid
Journal of Clinical Lipidology retweeted
We're heading into #NLAFall with an updated LDL-C Management Simplified, part of the Lipid Simplified Series published in @LipidJournal.
This updated manuscript distills the 2026 Dyslipidemia Guideline into practical, actionable guidance for clinicians managing LDL-C in both primary and secondary prevention settings. It incorporates the PREVENT ASCVD calculator for updated risk assessment and was designed with real-world practice in mind.
Whether you're heading to Orlando for #NLAFall, joining virtually, or simply staying current from your own practice, this is the ideal primer before the science kicks off.
🔗 Access the full article, print the infographics & find patient materials at lipid.org/resource/ldl-c-man….
#LDLCholesterol #DyslipidemiaGuidelines #ASCVD #CardiovascularPrevention
The JCL is pleased to announce two new issues are live! Check out the September Issue and our special Guidelines Issue.
🔗 September: lipidjournal.com/current
🔗 Guidelines: lipidjournal.com/issue/S1933…
New release: "Lipoprotein(a) Management Simplified: The National Lipid Association Lipid Simplified Series"
Read now & download the infographic: lipidjournal.com/article/S19…
In honor of #CholesterolMonth, the NLA is proud to release the second installment of the Lipids Simplified Series: Lipoprotein(a) Management Simplified.
Following the success of our LDL-C Management Simplified publication, we felt there was no more timely or necessary topic to tackle next than Lp(a).
Authored by leading Lp(a) experts Marlys L. Koschinsky, PhD, FNLA and Christie M. Ballantyne, MD, MNLA, this article and accompanying infographic are designed to distill the complexity surrounding Lp(a) into clear, actionable guidance for clinicians. Our goal is simple: make this essential science more accessible and easier to apply in everyday practice.
🔗 Access the full article and infographic at lipid.org/resource/lipoprote….
👉 You can find this and other NLA articles under the Articles section of our newly launched lipid.org.
Stay tuned... more topics in the Lipids Simplified Series are on the way!
#LipoproteinA #Lpa #ASCVD #CardiovascularPrevention
@CBallantyneMD @MarlysLPA
Happy #FHAwarenessDay!
What will it take to close the FH care gap? This #JCLSpotlight for #CholesterolMonth says it's multiple strategies working together, not just one fix. #KnowFH
Read more:
ow.ly/m9Cp50ZQMyb
#FHAwarenessDay is 1 day away!
This #JCLSpotlight for #CholesterolMonth explores how a structured transition model can help bridge the gap for young FH patients moving from pediatric to adult care. #KnowFH
🔗 ow.ly/5o6w50ZQCsF
2 days until #FHAwarenessDay!
Our #JCLSpotlight for #CholesterolMonth highlights how correcting LDL-C for Lp(a) improves FH diagnosis and reduces false positives. #KnowFH
Read more:
ow.ly/fgNl50ZQ9XC
#JCLSpotlight for #CholesterolMonth: Are lipid-lowering drugs safe during pregnancy? This Czech nationwide study offers new insight into maternal and fetal outcomes.
Read more:
ow.ly/f9os50ZNRqn
#JCLSpotlight for #CholesterolMonth: New research finds Lp(a) plasma levels have no major effect on coagulation phenotype, though high levels were associated with a mild increase in FV:C.
🔗 ow.ly/kTOf50ZNsZQ
Journal of Clinical Lipidology retweeted
Lp(a) and subclinical atherosclerosis: our new review of the association between Lp(a) and subclinical atherosclerosis, and the use of imaging for risk stratifying individuals with elevated Lp(a).
sciencedirect.com/science/ar…
@KhedagiApurva @yusi_gong @dharmajrmd @LipidJournal
Happy #CholesterolMonth! All month, we'll be highlighting the latest cholesterol-related research published in the JCL. First up in the #JCLSpotlight, from the Aug Edition: "Recurrence of CV events despite achieving LDL-C <1.4 mmol/L in patients w/ CAD": ow.ly/EqU850ZHK2a
Journal of Clinical Lipidology retweeted
Not an Lp(a) story this time, but relevant to residual lipid risk: after one ION775 dose, remnant-C, non-HDL-C and apoB fell at 6 months. APOC3 inhibition may be about particle burden, not TG alone #ESCCongress #EASSoMe @escardio @society_eas @Lpa_Doc @LipidJournal #JCLSpotlight
#ESCCongress Phase 1: one SC dose of APOC3 siRNA ION775 in moderate hypertriglyceridemia showed TG ↓ up to 68.4% at 6 months, sustained to 12 months in higher-dose cohorts @Lpa_Doc #JCLSpotlight
🔗 lipidjournal.com/article/S19…
#EASSoMe @escardio @society_eas @LipidJournal
Journal of Clinical Lipidology retweeted
#ESCCongress Phase 1: one SC dose of APOC3 siRNA ION775 in moderate hypertriglyceridemia showed TG ↓ up to 68.4% at 6 months, sustained to 12 months in higher-dose cohorts @Lpa_Doc #JCLSpotlight
🔗 lipidjournal.com/article/S19…
#EASSoMe @escardio @society_eas @LipidJournal
JCL Roundtable: Lipid metabolism, brain health, and dementia prevention. Recorded at #NLAFall in Scottsdale, Drs. Saeed, Trippi, Palta, Niotis, and Maki dig into this critical topic.
Have you read it yet?
lipidjournal.com/article/S19…
